Evidence map›Paper›PMID 34233636›Full record

ArticleBMC cancer2021

Descriptive epidemiological study of rare, less common and common cancers in Western Australia.

Gemma A Bilkey, Richard W Trevithick, Emily P Coles, Jennifer Girschik, Kristen J Nowak

Abstract read
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The Burden of Rare Cancers in North America.Journal of registry management · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gemma A BilkeyPatient Safety and Clinical Quality, Clinical Excellence Division, Department of Health, East Perth, Western Australia, 6004, Australia. Gemma.Bilkey@health.wa.gov.au.
Richard W TrevithickWestern Australian Cancer Registry, Clinical Excellence Division, Department of Health, East Perth, Western Australia, 6004, Australia.
Emily P ColesOffice of Population Health Genomics, Public and Aboriginal Health Division, Department of Health, East Perth, Western Australia, 6004, Australia.
Jennifer GirschikEpidemiology Branch, Public and Aboriginal Health Division, Department of Health, East Perth, Western Australia, 6004, Australia.
Kristen J NowakOffice of Population Health Genomics, Public and Aboriginal Health Division, Department of Health, East Perth, Western Australia, 6004, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are no epidemiological studies describing rare cancers in Western Australia (WA). We aimed to fill this gap by estimating the incidence and five-year survival of rare, less common and common cancers in WA, based on definitions for rarity used by the Australian Institute of Health and Welfare and cancer groupings from the project on Surveillance of Rare Cancers in Europe (RARECARE). This research will enable policy- and decision-makers to better understand the size and nature of the public health problem presented by rare cancers in WA. It is anticipated that this study will inform improved health service design and delivery for all WA cancer patients, but particularly those with rare and less common cancers.

methodsWe estimated incidence and five-year survival rates of rare, less common and common cancers in WA using data sourced from the WA Cancer Registry for the 2013-2017 period. Cancers were defined as rare (< 6), less common (6-12), or common (> 12) based on their crude incidence rate per 100,000 people per year.

resultsRare cancers make up 21.5% of all cancer diagnoses in WA, with a significantly poorer five-year survival of 58.2% (95% confidence interval (CI) 57.3-59.1%), compared to patients diagnosed with a common cancer, whose five-year survival was 87.8% (95% CI 87.3-88.3%). Survival for less common cancers was significantly poorer than both rare and common cancers, at 48.1% (95% CI 47.3-49.0%). Together, rare and less common cancers represent 48.4% of all cancer diagnoses in WA.

conclusionsWhile rare cancers are individually scarce, collectively over one in five cancer patients in WA are diagnosed with a rare cancer. These patients experience significantly worse prognoses compared to patients with common cancers.

Indexed as

AdolescentAdultAgedAged, 80 and overChildChild, PreschoolHumansInfantInfant, NewbornMaleMiddle AgedNeoplasmsRare DiseasesSurvival AnalysisWestern AustraliaYoung AdultEpidemiologyIncidenceLess common cancerRare cancerRARECARESurvivalWestern Australia

Identifiers

PMID34233636
PMCPMC8265087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.